New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2013
05:55 EDTAGN, AGN, SE, SE, NYX, NYX, K, K, EL, EL, EMR, EMR, ETN, ETN, DO, DO, DLPH, DLPH, CSC, CSC, CAH, CAH, BDX, BDX, ADP, ADP, ADM, ADM, TE, TECompanies reporting Before the Market Open on Tuesday, February 5
Notable companies reporting before the opening bell include Allergan (AGN), Archer Daniels Midland (ADM), Automatic Data Processing (ADP), Becton Dickinson and Co (BDX), Cardinal Health (CAH), Computer Sciences (CSC), Delphi Automotive (DLPH), Diamond Offshore Drilling (DO), Eaton (ETN), Emerson Electric (EMR), Estee Lauder Companies (EL), Kellogg (K), NYSE Euronext (NYX), Spectra Energy (SE) and TECO Energy (TE).
News For AGN;ADM;ADP;BDX;CAH;CSC;DLPH;DO;ETN;EMR;EL;K;NYX;SE;TE From The Last 14 Days
Check below for free stories on AGN;ADM;ADP;BDX;CAH;CSC;DLPH;DO;ETN;EMR;EL;K;NYX;SE;TE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
July 21, 2014
08:07 EDTAGNAllergan: Approx. 94% of customer-facing personnel unaffected by restructuring
Subscribe for More Information
08:06 EDTAGNAllergan sees Q3 EPS $1.44-$1.47, consensus $1.45
Subscribe for More Information
08:05 EDTAGNAllergan sees FY14 total net product sales $6.9B-$7.05B
Sees total specialty pharamceuticals net sales $5.87B-$5.98B, total core medical devices net sales $1.01B-$1.05B. Sees FY BOTOX net sales $2.2B-$2.28B, LATISSE net sales $100M. Sees effective tax rate on non-GAAP earnings between 26% and 27%.
08:03 EDTAGNAllergan sees FY14 EPS $5.74-$5.80, consensus $5.70
Allergan reconfirms its aspiration of double digit sales growth across the strategic plan period (2014 through 2019), as the planned reductions in selling, general and administrative expenses and reduced focus on lower-value spend will have only a modest impact on the net sales growth. Allerganís strategic plan (2014 through 2019) is expected to deliver a compounded annual growth rate of greater than 20% EPS growth. Allergan estimates 2014 EPS between $5.74 and $5.80. Allergan estimates 2015 EPS between $8.20 and $8.40. Allergan estimates 2016 EPS at approximately $10.00. Allergan currently estimates that it will incur total non-recurring pre-tax charges of between $375 million and $425 million in connection with the restructuring and other costs, of which $65 million to $75 million will be a non-cash charge associated with the acceleration of previously unrecognized share-based compensation costs and certain other non-cash accounting adjustments. The restructuring charges and other costs will primarily consist of employee severance and other one-time termination benefits, facility lease and other contract terminations, accelerated depreciation and asset write-downs, accelerated equity-based compensation, temporary labor and duplicate operating expenses. These non-recurring charges will be incurred beginning in the third quarter of 2014 and are expected to continue through the second quarter of 2015.
08:02 EDTAGNAllergan to reduce workforce by approx. 1,500 employees
Subscribe for More Information
08:01 EDTAGNAllergan reports Q2 adjusted EPS $1.51, consensus $1.44
Reports Q2 revenue $1.86B, consensus $1.77B.
07:15 EDTAGNValeant Allergan contacts Quebec, U.S. regulators regarding Allergan statements
Valeant (VRX) has contacted both the Autorite des marches financiers in Quebec and the SEC regarding Allergan (AGN) apparent attempt to "mislead investors and manipulate the market for Valeant common shares by continuing to make false and misleading statements regarding Valeant's business despite Valeant's public statements correcting such information." The latest statements were made last Friday when Allergan asserted in an SEC filing that Bausch + Lomb's pharmaceutical sales were stagnant or declining. Valeant's decision to contact the authorities also reflects concerns raised by several Canadian Valeant shareholders about comments made about Valeant by Allergan's management during recent meetings with these investors in Canada.
07:09 EDTAGNValeant, Ackman go to SEC over Allergan claims, CNBC reports
Subscribe for More Information
06:34 EDTAGNCapital Research sells nearly all its Allergan stake, WSJ reports
Subscribe for More Information
July 18, 2014
16:46 EDTETNEaton narrows Q2 adjusted EPS view to $1.10-$1.12 from $1.05-$1.15
Subscribe for More Information
12:51 EDTAGNKey GOP senator signals readiness for inversion deal, The Hill says
Subscribe for More Information
11:27 EDTAGNSamlyn undecided on support for Valeant bid for Allergan, Dow says
Subscribe for More Information
July 17, 2014
16:45 EDTAGNPershing Square looks to obtain consents for special meeting
Subscribe for More Information
10:20 EDTAGNPershing sees coming 13-Fs to show long-term Allergan holders have been selling
Subscribe for More Information
10:00 EDTELOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:00 EDTAGNAckman says large takeover by Allergan could be 'enormously value destructive'
08:44 EDTAGNPershing says special meeting warranted given 'poor governance' at Allergan
Subscribe for More Information
07:46 EDTDLPHSenate Commerce & Transportation Committee to hold a hearing
The Subcommittee on Consumer Protection, Product Safety and Insurance holds a hearing entitled, "Examining Accountability and Corporate Culture in Wake of the GM Recalls" with General Motors CEO Barra and EVP Milllikin and President & CEO O'Neal of Delphi Automotive on July 17 at 10 am. Webcast Link
07:33 EDTELEstee Lauder initiated with a Buy at Argus
Target $88.
07:00 EDTAGNPaulson says Allergan could be wroth $220 per share, WSJ reports
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use